Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$142,000.

  • Ironwood Pharmaceuticals' Cash from Investing Activities rose 87.50% to -$2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51,000, marking a year-over-year increase of 98.82%. This contributed to the annual value of -$142,000 for FY2024, which is 99.99% up from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Cash from Investing Activities stood at -$142,000, which was up 99.99% from -$1.0 billion recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Investing Activities peaked at -$136,000 during FY2022, and registered a low of -$1.0 billion during FY2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Cash from Investing Activities had a median value of -$142,000 in 2024 and averaged -$342.2 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Cash from Investing Activities slumped by 754,545.59% in 2023, and later spiked by 99.99% in 2024.
  • Ironwood Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$1.8 million in 2020, then soared by 85.61% to -$265,000 in 2021, then soared by 48.68% to -$136,000 in 2022, then slumped by 754,545.59% to -$1.0 billion in 2023, then surged by 99.99% to -$142,000 in 2024.